TY - JOUR T1 - Previously infected vaccinees broadly neutralize SARS-CoV-2 variants JF - medRxiv DO - 10.1101/2021.04.25.21256049 SP - 2021.04.25.21256049 AU - Hans C. Leier AU - Timothy A. Bates AU - Zoe L. Lyski AU - Savannah K. McBride AU - David X. Lee AU - Felicity J. Coulter AU - James R. Goodman AU - Zhengchun Lu AU - Marcel E. Curlin AU - William B. Messer AU - Fikadu G. Tafesse Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/29/2021.04.25.21256049.abstract N2 - We compared the serum neutralizing antibody titers before and after two doses of the BNT162b2 COVID-19 vaccine in ten individuals who recovered from SARS-CoV-2 infection prior to vaccination to 20 individuals with no history of infection, against clinical isolates of B.1.1.7, B.1.351, P.1, and the original SARS-CoV-2 virus. Vaccination boosted pre-existing levels of anti-SARS-CoV-2 spike antibodies 10-fold in previously infected individuals, but not to levels significantly higher than those of uninfected vaccinees. However, neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees against every variant tested: 5.2-fold against B.1.1.7, 6.5-fold against B.1.351, 4.3-fold against P.1, and 3.4-fold against original SARS-CoV-2. Our study indicates that a first-generation COVID-19 vaccine provides broad protection from SARS-CoV-2variants in individuals with previous infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by the M.J. Murdock Charitable Trust, National Institutes of Health training grant T32AI747225, Oregon Health & Science University Innovative IDEA grant 1018784, and National Institutes of Health grant R01AI145835. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in accordance with the Oregon Health & Science University Institutional Review Board (IRB#00022511).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in this manuscript is available upon request from the corresponding authors, M.E.C. (curlin@ohsu.edu), W.B.M. (messer@ohsu.edu), and F.G.T. (tafesse@ohsu.edu). ER -